Featured
| Nov 13 | US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder read more » |
| Nov 13 | One-time gene therapy reverses liver disease MASH in mouse models read more » |
| Nov 11 | Autolus secures FDA approval for CAR-T cell therapy use in ALL read more » |
| Nov 14 | Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy read more » |
| Nov 13 | Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies read more » |
| Nov 13 | Ireland's SSPC and NIBRT Team to Take on Biopharma Bottlenecks read more » |
| Nov 13 | Biden officials warn of threat to U.S. children if anti-vaccine views prevail read more » |
| Nov 13 | Inflammation-reducing molecule provides a new target for treating atherosclerosis read more » |
| Nov 07 | Sarepta scraps a Duchenne drug as gene therapy sales rise read more » |
| Nov 13 | Directed evolution of engineered virus-like particles with improved production and transduction efficiencies read more » |
| Nov 12 | Multimodal scanning of genetic variants with base and prime editing read more » |
| Nov 12 | A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases | Nature Communications read more » |
| Nov 11 | The disparate burden of infectious diseases | Gene Therapy read more » |
| Nov 11 | Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies read more » |
| Nov 08 | Binding-driven forward tearing protospacer activated CRISPR-Cas12a system and applications for microRNA detection read more » |
| Nov 08 | Neuroimaging Applications for the Delivery and Monitoring of Gene Therapy for Central Nervous System Diseases read more » |
| Nov 07 | Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles read more » |
PackGene’s Newsletter
Receive the latest news and insights to your inbox.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
One-time gene therapy reverses liver disease MASH in mouse models
Credit: Molecular Therapy (2024). DOI: 10.1016/j.ymthe.2024.10.023UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than...
PTC Therapeutics Achieves FDA Approval for First Brain-Administered Gene Therapy
Breakthrough Approval for Kebilidi The FDA has granted a landmark approval to PTC Therapeutics' Kebilidi, making it the first gene therapy in the U.S. to be administered directly into the brain. This approval represents a major step forward in gene therapy, offering...
FDA Approves Autolus’ New CAR-T Therapy for Aggressive Blood Cancer
In a significant development for cancer treatment, the US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ CAR-T cell therapy for adult patients with relapsed or treatment-resistant B cell precursor acute lymphoblastic leukemia (B-ALL). This...
Inflammation-reducing molecule provides a new target for treating atherosclerosis
Systemic metrics of atherosclerosis resolution in dietary cessation CPC model. Credit: Cell Reports (2024). DOI: 10.1016/j.celrep.2024.114911Researchers at Case Western Reserve University have identified a new target to treat atherosclerosis, a condition where plaque...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
